Insulet Corp. (NASDAQ:PODD)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a report released on Thursday. They presently have a $48.00 target price on the stock. Wedbush’s target price points to a potential upside of 31.26% from the company’s current price.

Several other analysts have also commented on the stock. B. Riley reaffirmed a “neutral” rating and set a $40.00 price target on shares of Insulet Corp. in a research report on Wednesday, November 9th. Zacks Investment Research lowered shares of Insulet Corp. from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 9th. Leerink Swann reaffirmed an “outperform” rating and set a $50.00 price target (down previously from $55.00) on shares of Insulet Corp. in a research report on Monday, November 7th. Canaccord Genuity set a $39.00 price target on shares of Insulet Corp. and gave the company a “hold” rating in a research report on Sunday, November 6th. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $38.00 price target on shares of Insulet Corp. in a research report on Friday, November 4th. Seven analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $42.15.

Analyst Recommendations for Insulet Corp. (NASDAQ:PODD)

Shares of Insulet Corp. (NASDAQ:PODD) opened at 36.57 on Thursday. The firm’s 50-day moving average price is $37.98 and its 200-day moving average price is $36.09. The stock’s market cap is $2.10 billion. Insulet Corp. has a 12-month low of $23.94 and a 12-month high of $45.60.

Insulet Corp. (NASDAQ:PODD) last released its earnings results on Thursday, November 3rd. The company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.04. Insulet Corp. had a negative net margin of 12.95% and a negative return on equity of 87.46%. The business had revenue of $94.90 million for the quarter, compared to analyst estimates of $89.75 million. During the same period last year, the company posted ($0.33) EPS. The business’s revenue was up 32.5% on a year-over-year basis. On average, analysts forecast that Insulet Corp. will post ($0.37) EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in PODD. Geneva Advisors LLC boosted its stake in Insulet Corp. by 0.3% in the second quarter. Geneva Advisors LLC now owns 19,923 shares of the company’s stock valued at $602,000 after buying an additional 59 shares during the period. Principal Financial Group Inc. boosted its stake in Insulet Corp. by 0.9% in the second quarter. Principal Financial Group Inc. now owns 7,673 shares of the company’s stock valued at $232,000 after buying an additional 71 shares during the period. ProShare Advisors LLC boosted its stake in Insulet Corp. by 1.6% in the second quarter. ProShare Advisors LLC now owns 7,055 shares of the company’s stock valued at $213,000 after buying an additional 108 shares during the period. Sei Investments Co. boosted its stake in Insulet Corp. by 2.4% in the second quarter. Sei Investments Co. now owns 8,452 shares of the company’s stock valued at $255,000 after buying an additional 201 shares during the period. Finally, Virginia Retirement Systems ET AL boosted its stake in Insulet Corp. by 2.3% in the third quarter. Virginia Retirement Systems ET AL now owns 13,500 shares of the company’s stock valued at $553,000 after buying an additional 300 shares during the period.

About Insulet Corp.

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM).

5 Day Chart for NASDAQ:PODD

Receive News & Stock Ratings for Insulet Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corp. and related stocks with our FREE daily email newsletter.